Advertisement

Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017

  • Michele Maio
  • Maria Fortunata Lofiego
  • Carolina Fazio
  • Sara Cannito
  • Carla Chiarucci
  • Gianluca Giacobini
  • Monica Valente
  • Patrizia Tunici
  • Alessia Covre
  • Vincenzo Russo
Meeting Report

Introduction

The XV annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) took place in Siena, Tuscany, on October 5–7, 2017. International leading scientists from academic institutions and pharmaceutical companies presented updates on new research achievements in cancer bio-immunotherapy. The meeting aimed to build a close connection between clinical and pre-clinical research. Many topics were discussed during the meeting, such as (a) tumor microenvironment; (b) epigenetics, immune cells and cancer; (c) commensal microorganisms, food, immune cells and cancer; (d) immune agonists and antagonists; (e) active and adoptive immunotherapy; (f) prospective NIBIT and NIBIT Foundation collaborations. There follows a brief summary of the topics discussed in the meeting.

Session 1: tumor microenvironment 1

Growing experimental evidence points to a significant role of the host immune system and its interactions with cancer cells inside the tumor microenvironment (TME) in modulating...

Keywords

Immunotherapy Cancer vaccines Checkpoint blockade agents Targeted therapies NIBIT Tumor microenvironment 

Abbreviations

ACT

Adoptive cell therapy

APM

Antigen-presenting machinery

BM

Bone marrow

CAR

Chimeric antigen receptors

CDA

Cytidine deaminase

CSC

Cancer stem cells

DC

Dendritic cells

DCR

Disease control rate

DITC

Dacarbazine

GIC

Italian society of cytometry

GITR

Glucocorticoid-induced tumor necrosis factor receptor

HF

Heart failure

HMA

Hypomethylating agent

ICI

Immune checkpoint inhibitors

IDO1

Indoleamine 2,3-dioxygenase-1

iNKT

Invariant natural killer T cells

MDP

Mutations and drugs portal

MDSC

Myeloid-derived suppressor cells

Macrophage orchestration

MSA

Methylseleninic acid

MV

Microvesicles

NSCLC

Non-small cell lung cancer

ORR

Objective response rate

OS

Overall survival

PCa

Prostate cancer

PDAC

Pancreatic ductal adenocarcinoma

pDC

Plasmacytoid dendritic cells

ROS

Reactive oxygen species

STS

Short-term starvation

TAM

Tumor-associated macrophages

TCF-1

Transgenic T-cell factor 1

TCR

T-cell receptors

TENM4

Teneurin-4

TIL

Tumor-infiltrating lymphocytes

TLS

Tertiary lymphoid structures

TME

Tumor microenvironment

TNBC

Triple-negative breast cancer

TNFR

Tumor necrosis factor receptor

Treg

Regulatory T cells

T-VEC

Talimogene laherparepvec

Notes

Acknowledgements

This meeting was organized in collaboration with the Board of Directors of NIBIT and with NIBIT Foundation.

Author contributions

Michele Maio, Maria Fortunata Lofiego, Carolina Fazio, Sara Cannito, Carla Chiarucci, Gianluca Giacobini, Alessia Covre contributed to writing the summary of the different meeting sessions; Vincenzo Russo, Monica Valente, Patrizia Tunici, Alessia Covre, and Michele Maio supervised and critically contributed to the final revision of the manuscript.

Funding

This meeting was supported in part by grants from Bristol-Meyers Squibb, Incyte, Merck Sharp & Dohme Corp. Oncology, Roche, Astex pharmaceuticals, Amgen, AstraZeneca and Merck Serono.

Compliance with ethical standards

Conflict of interest

Michele Maio is a consultant/advisory board member for Bristol-Meyers Squibb, Incyte, Merck Sharp & Dohme Corp. Oncology, Roche, Astex pharmaceuticals, Amgen, AstraZeneca and Merck Serono. No potential conflicts of interest were disclosed by the other authors.

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Michele Maio
    • 1
    • 2
  • Maria Fortunata Lofiego
    • 2
  • Carolina Fazio
    • 2
  • Sara Cannito
    • 2
    • 3
  • Carla Chiarucci
    • 2
  • Gianluca Giacobini
    • 2
  • Monica Valente
    • 2
  • Patrizia Tunici
    • 2
  • Alessia Covre
    • 2
  • Vincenzo Russo
    • 1
    • 4
  1. 1.Italian Network for Tumor Bio-immunotherapy (NIBIT)SienaItaly
  2. 2.Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of SienaIstituto Toscano TumoriSienaItaly
  3. 3.University of SienaSienaItaly
  4. 4.Immuno-biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental OncologySan Raffaele Hospital Scientific InstituteMilanItaly

Personalised recommendations